East China's Shandong province hosted a cooperation and exchange meeting with multinational pharmaceutical companies in Shanghai on March 1.

Representatives of more than 20 global pharmaceutical giants, including Astrazeneca, GlaxoSmithKline, Johnson & Johnson, Pfizer and Bayer, as well as representatives from the American Chamber of Commerce in Shanghai and other organizations, were invited to the event.

Shandong boosts exchanges with multinational pharmaceutical companies. [Photo/Dazhong News]

Cui Hongguang, deputy director of the Shandong Provincial Department of Commerce, said that the medical care and health industry is one of the "top 10" in Shandong, and has developed vigorously and gained momentum in an all-round way in recent years.

During the 14th Five-Year Plan period (2021-25), Shandong will continue to promote the high-quality development of the pharmaceutical industry, improve the efficiency of innovation, accelerate the digital transformation, and realize all-round mutually beneficial cooperation with pharmaceutical multinational companies in industrial investment, supply chain connection, trade circulation, research and development and innovation, digital development and other fields, so as to build Shandong into a new highland of the pharmaceutical industry across the world, according to Cui.

Representatives from Astrazeneca described the excellent services provided by Shandong during the implementation of its project in the province, and praised the sound business environment in Shandong.

Officials from Jinan, Qingdao, Yantai, Weihai and Heze also introduced in detail their individual investment environment and supporting policies for the pharmaceutical industry.

Representatives of global pharmaceutical giants, business organizations and government departments attend the event. [Photo/Dazhong News]